Risk of hand-foot skin reaction associated with VEGFR-TKIs: a meta-analysis of 57 randomized controlled trials involving 24956 patients.
Multiple randomized controlled trials have assessed hand-foot skin reaction (HFSR) caused by vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs). We performed a meta-analysis in order to determine the incidence and the relative risk (RR) of HFSR associated with these agents. Databases were searched for relevant studies. Statistical analyses were conducted to calculate the summary incidences, relative risk (RR) and 95% confidence intervals (CIs) by using either random-effects or fixed-effects models according to the heterogeneity of the included studies. A total of 24956 patients from 57 studies were included. The overall incidence of all-grade and high-grade HFSR associated with VEGFR-TKIs was 35.0% (95% CI, 28.6-41.6%) and 9.7% (95% CI, 7.3-12.3%), respectively. The use of VEGFR-TKIs significantly increased the risk of developing all-grade (RR, 5.09; 95% CI, 3.52-7.35; P < 0.001) and high-grade (RR, 9.42; 95% CI, 5.59-15.90; P < 0.001) HFSR. Subgroup analyses revealed that the risk of HFSR was significantly increased according to tumor type, VEGFR-TKI, trial phase, treatment regimen, and control therapy. No evidence of publication bias was observed. High heterogeneity in most studies. Cancer patients receiving VEGFR-TKIs are at high risk of developing HFSR.